Perocchio M, Gigli G, Barra M, Sacchetti R, Vallebona A, Rosolen G A, Orlandi S
Servizio di Cardiologia, UTIC, Ospedale di Rapallo, Genova.
Minerva Cardioangiol. 1996 Mar;44(3):115-21.
The search for the ideal antihypertensive drug is ongoing. Carvedilol is a new beta-adrenoceptor antagonist which also causes peripheral vasodilation primarily via alpha 1-adrenergic blockade. Twenty patients with mild to moderate essential hypertension and previous intolerance and side effects to other antihypertensive drugs were studied. After initial baseline assessment, patients received 25 mg carvedilol orally q.d. The treatment lasted 60 days. In our study carvedilol was well tolerated and no important side effect was recorded. Blood pressure decreased significantly to normal values, without orthostatic blood pressure decreases. Heart rate decreased significantly too, but no significant bradycardia was induced. No negative effects on serum lipids and no clinical evidence of increase in peripheral resistance were observed. Ventricular arrhythmia on Holter monitoring were significantly reduced after treatment with carvedilol.
对理想抗高血压药物的研究仍在进行中。卡维地洛是一种新型β-肾上腺素能受体拮抗剂，它主要通过α1-肾上腺素能阻滞作用引起外周血管舒张。对20例轻度至中度原发性高血压患者进行了研究，这些患者既往对其他抗高血压药物不耐受且有副作用。在进行初始基线评估后，患者口服25mg卡维地洛，每日一次。治疗持续60天。在我们的研究中，卡维地洛耐受性良好，未记录到重要的副作用。血压显著下降至正常水平，无直立性血压下降。心率也显著下降，但未诱发明显的心动过缓。未观察到对血脂有负面影响，也没有外周阻力增加的临床证据。使用卡维地洛治疗后，动态心电图监测的室性心律失常显著减少。
